Eydenzelt is subjecting Eylea to further biosimilar erosion, though Regeneron hopes to offset this with two new approvals for ...

The proportion of children receiving a second dose of the MMR vaccine is still below the threshold to stop viral transmission ...

With an eye on 2026, the healthcare editorial team reflects on key takeaways and trends from recent pharma conferences.

In 2024, over half of patients found to have HIV in Europe received a late diagnosis, which is often associated with poor ...

Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by ...

The UK MHRA has granted approval to Roche Products’ inavolisib to treat adults diagnosed with HR-positive, HER2-negative ...

IASO Biotechnology has received the Hong Kong Department of Health approval for its BLA submitted for the fully human ...

This licensing deal falls under SK's wider ploy to harness the growing promise of radiopharmaceuticals within the oncology ...

As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to ...

The US FDA has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax.

Novartis' Stein site will discontinue solid dose manufacturing in favour of sterile dose and cell & gene therapy production, ...

With a population of over 670 million people in ASEAN, the total number of patients experiencing rare diseases and conditions ...